Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2018-08-07 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2018-08-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 6, 2018, reporting the company's financial results for the three and six months ended June 30, 2018. It specifically mentions a press release announcing these financial results is furnished as an exhibit. The document is short (3041 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis itself. According to the rules, initial announcements of quarterly or periodical financial results (key highlights only) are classified as Earnings Release (ER). The presence of a press release announcing financial results aligns with the ER category rather than a full interim report (IR) or annual report (10-K).
2018-08-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content discusses a Supplemental Indenture related to convertible senior notes, a legal complaint filed against the company regarding this indenture, and references to exhibits attached. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, dividend notice, or management discussion. It is a regulatory filing reporting a material event (legal and contractual update) as required by the SEC. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (5466 characters) and detailed event description support this classification with high confidence.
2018-07-30 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 9, 2018, by Ligand Pharmaceuticals Incorporated. It announces a Research & Development Agreement between Ligand's subsidiary and Janssen Research & Development, LLC. The content focuses on the agreement details and potential milestone payments, not on financial results or detailed financial statements. The document length is 3949 characters, which is relatively short and typical for an 8-K filing announcing a material event or agreement. There is no indication of financial data, audit information, or management discussion. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for SEC filings that do not fit other specific categories and typically includes 8-K filings reporting material events.
2018-07-11 English
PRIMARY DOCUMENT
Director's Dealing
2018-07-04 English
PRIMARY DOCUMENT
Director's Dealing
2018-07-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.